BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Date AA, Vitoria M, Granich R, Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ. 2010;88:253-259. [PMID: 20431788 DOI: 10.2471/blt.09.066522] [Cited by in Crossref: 50] [Cited by in F6Publishing: 65] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Müller P, Velez Lapão L. Mixed methods systematic review and metasummary about barriers and facilitators for the implementation of cotrimoxazole and isoniazid—Preventive therapies for people living with HIV. PLoS ONE 2022;17:e0251612. [DOI: 10.1371/journal.pone.0251612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chanie ES, Tesgera Beshah D, Ayele AD. Incidence and predictors of attrition among children on antiretroviral therapy at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2019: Retrospective follow-up study. SAGE Open Medicine 2022;10:205031212210778. [DOI: 10.1177/20503121221077843] [Reference Citation Analysis]
3 Mulugeta T, Takale A, Umeta B, Terefe B. Active TB infection and its associated factors among HIV-1 infected patients at Jimma medical center, Southwest Ethiopia. J Pharm Health Care Sci 2021;7:44. [PMID: 34865659 DOI: 10.1186/s40780-021-00228-5] [Reference Citation Analysis]
4 Müller P, Velez Lapão L. Mixed methods systematic review and metasummary about barriers and facilitators for the implementation of cotrimoxazole and isoniazid – preventive therapies for people living with HIV.. [DOI: 10.1101/2021.04.30.21256370] [Reference Citation Analysis]
5 Chanie ES, Feleke DG, Asnakew S, GebreEyesus FA, Tesfaw A, Bayih WA, Tigabu A, Anyalem YA, Amare AT, Belay DM, Dagnaw FT, Abate BB. Time to detection of anemia and its predictors among children living with HIV at Debre Tabor and University of Gondar Compressive Specialized Hospitals, 2020: a multicentre retrospective follow-up study. BMC Pediatr 2021;21:151. [PMID: 33785009 DOI: 10.1186/s12887-021-02616-0] [Reference Citation Analysis]
6 Guzzo MB, Li Q, Nguyen HV, Boom WH, Nguyen L. The Pup-Proteasome System Protects Mycobacteria from Antimicrobial Antifolates. Antimicrob Agents Chemother 2021;65:e01967-20. [PMID: 33468462 DOI: 10.1128/AAC.01967-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Tafere C, Yilma Z, Abrha S, Yehualaw A. Formulation, in vitro characterization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression. PLoS One 2021;16:e0246648. [PMID: 33725014 DOI: 10.1371/journal.pone.0246648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Buck WC, Nguyen H, Siapka M, Basu L, Greenberg Cowan J, De Deus MI, Gleason M, Ferreira F, Xavier C, Jose B, Muthemba C, Simione B, Kerndt P. Integrated TB and HIV care for Mozambican children: temporal trends, site-level determinants of performance, and recommendations for improved TB preventive treatment. AIDS Res Ther 2021;18:3. [PMID: 33422091 DOI: 10.1186/s12981-020-00325-9] [Reference Citation Analysis]
9 Boettiger DC, Law MG, Sohn AH, Davies MA, Wools-Kaloustian K, Leroy V, Yotebieng M, Vinikoor M, Vreeman R, Amorissani-Folquet M, Edmonds A, Fatti G, Batte J, Renner L, Adedimeji A, Kariminia A; International Epidemiology Databases to Evaluate AIDS. Temporal Trends in Co-trimoxazole Use Among Children on Antiretroviral Therapy and the Impact of Co-trimoxazole on Mortality Rates in Children Without Severe Immunodeficiency. J Pediatric Infect Dis Soc 2019;8:450-60. [PMID: 30215763 DOI: 10.1093/jpids/piy087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Johnson LF, Anderegg N, Zaniewski E, Eaton JW, Rebeiro PF, Carriquiry G, Nash D, Yotebieng M, Ekouevi DK, Holmes CB, Choi JY, Jiamsakul A, Bakoyannis G, Althoff KN, Sohn AH, Yiannoutsos C, Egger M; International epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration. Global variations in mortality in adults after initiating antiretroviral treatment: an updated analysis of the International epidemiology Databases to Evaluate AIDS cohort collaboration. AIDS 2019;33 Suppl 3:S283-94. [PMID: 31800405 DOI: 10.1097/QAD.0000000000002358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
11 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
12 Nigatu D, Dinegde NG, Sendo EG. Cotrimoxazole Prophylaxis Treatment Adherence and Associated Factors Among Human Immunodeficiency Virus (HIV) Exposed Children in Public Hospitals in Ilubabor Zone, Southwest Ethiopia, 2018. TOPHJ 2019;12:184-198. [DOI: 10.2174/1874944501912010184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Azimi S, Sabokbar A, Bairami A, Gharavi MJ. Evaluation of Three Different Laboratory Methods for Identification of Pneumocystis jirovecii Pneumonia (PCP) among HIV Positive Asymptomatic Prisoners. Iran J Parasitol 2019;14:280-7. [PMID: 31543916] [Reference Citation Analysis]
14 Wambiya EOA, Atela M, Eboreime E, Ibisomi L. Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study. BMJ Open 2018;8:e024286. [PMID: 30573488 DOI: 10.1136/bmjopen-2018-024286] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
15 Ousley J, Soe KP, Kyaw NTT, Anicete R, Mon PE, Lwin H, Win T, Cristofani S, Telnov A, Fernandez M, Ciglenecki I. IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence. Public Health Action 2018;8:20-4. [PMID: 29581939 DOI: 10.5588/pha.17.0087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Maharaj B, Gengiah TN, Yende-Zuma N, Gengiah S, Naidoo A, Naidoo K. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. Int J Tuberc Lung Dis 2017;21:537-43. [PMID: 28399969 DOI: 10.5588/ijtld.16.0775] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
17 Cranmer LM, Langat A, Ronen K, McGrath CJ, LaCourse S, Pintye J, Odeny B, Singa B, Katana A, Nganga L, Kinuthia J, John-Stewart G. Integrating tuberculosis screening in Kenyan Prevention of Mother-To-Child Transmission programs. Int J Tuberc Lung Dis 2017;21:256-62. [PMID: 28225335 DOI: 10.5588/ijtld.16.0478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Howard AA, Hirsch-Moverman Y, Saito S, Gadisa T, Daftary A, Melaku Z. The ENRICH Study to evaluate the effectiveness of a combination intervention package to improve isoniazid preventive therapy initiation, adherence and completion among people living with HIV in Ethiopia: rationale and design of a mixed methods cluster randomized trial. Contemp Clin Trials Commun 2017;6:46-54. [PMID: 28626811 DOI: 10.1016/j.conctc.2017.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Diese M, Shrestha L, Pradhan B, Singh D, Raaijmakers H, Kisesa A, Chamla D, Ntambue MA. Bottlenecks and opportunities for delivering integrated pediatric HIV services in Nepal. Curr Opin HIV AIDS 2016;11 Suppl 1:S21-9. [PMID: 26945139 DOI: 10.1097/COH.0000000000000262] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
20 Guzzo MB, Nguyen HT, Pham TH, Wyszczelska-Rokiel M, Jakubowski H, Wolff KA, Ogwang S, Timpona JL, Gogula S, Jacobs MR, Ruetz M, Kräutler B, Jacobsen DW, Zhang GF, Nguyen L. Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa Drugs. PLoS Pathog 2016;12:e1005949. [PMID: 27760199 DOI: 10.1371/journal.ppat.1005949] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
21 Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health 2016;16:840. [PMID: 27543096 DOI: 10.1186/s12889-016-3525-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
22 Boettiger DC, Muktiarti D, Kurniati N, Truong KH, Saghayam S, Ly PS, Hansudewechakul R, Van Nguyen L, Do VC, Sudjaritruk T, Lumbiganon P, Chokephaibulkit K, Bunupuradah T, Nik Yusoff NK, Wati DK, Mohd Razali KA, Fong MS, Nallusamy RA, Sohn AH, Kariminia A; Therapeutics Research, Education, and AIDS Training in Asia (TREAT Asia) Pediatric HIV Observational Database. Early Height and Weight Changes in Children Using Cotrimoxazole Prophylaxis With Antiretroviral Therapy. Clin Infect Dis 2016;63:1236-44. [PMID: 27470239 DOI: 10.1093/cid/ciw514] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
23 Gebresillassie BM, Gebeyehu MB, Abegaz TM, Erku DA, Mekuria AB, Tadesse YD. Evaluation of cotrimoxazole use as a preventive therapy among patients living with HIV/AIDS in Gondar University Referral Hospital, northwestern Ethiopia: a retrospective cross-sectional study. HIV AIDS (Auckl) 2016;8:125-33. [PMID: 27462178 DOI: 10.2147/HIV.S103081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
24 Kunkel A, Colijn C, Lipsitch M, Cohen T. How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philos Trans R Soc Lond B Biol Sci 2015;370:20140306. [PMID: 25918446 DOI: 10.1098/rstb.2014.0306] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
25 Kamuhabwa AA, Manyanga V. Challenges facing effective implementation of co-trimoxazole prophylaxis in children born to HIV-infected mothers in the public health facilities. Drug Healthc Patient Saf 2015;7:147-56. [PMID: 26604825 DOI: 10.2147/DHPS.S89115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
26 Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One 2015;10:e0142290. [PMID: 26551023 DOI: 10.1371/journal.pone.0142290] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
27 Yotebieng M, Edmonds A, Lelo P, Wenzi LK, Ndjibu PT, Lusiama J, Kabuayi JP, Behets F. High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo. AIDS 2015;29:2055-7. [PMID: 26352882 DOI: 10.1097/QAD.0000000000000791] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
28 Daniel OJ, Adejumo OA, Gidado M, Abdur-Razzaq HA, Jaiyesimi EO. HIV-TB co-infection in children: associated factors and access to HIV services in Lagos, Nigeria. Public Health Action 2015;5:165-9. [PMID: 26399285 DOI: 10.5588/pha.15.0027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
29 Peters JA, Heunis C, Kigozi G, Osoba T, van der Walt M. Integration of TB-HIV services at an ANC facility in Frances Baard District, Northern Cape, South Africa. Public Health Action 2015;5:30-5. [PMID: 26400599 DOI: 10.5588/pha.14.0033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
30 Shayo GA, Moshiro C, Aboud S, Bakari M, Mugusi FM. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania. BMC Infect Dis 2015;15:368. [PMID: 26306511 DOI: 10.1186/s12879-015-1085-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
31 Saadani Hassani A, Marston BJ, Kaplan JE. Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review. J Acquir Immune Defic Syndr 2015;68 Suppl 3:S257-69. [PMID: 25768865 DOI: 10.1097/QAI.0000000000000486] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
32 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virology 2015; 4(2): 105-112 [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
33 Cheng W, Wu Y, Wen Y, Ma Y, Zhao D, Dou Z, Zhang W, Bulterys M, Zhang F. Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China. Bull World Health Organ 2015;93:152-60. [PMID: 25838611 DOI: 10.2471/BLT.14.142745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
34 Zetola NM, Macesic N, Shin SS, Peloso A, Ncube R, Klausner JD, Modongo C, Collman RG. Longer hospital stay is associated with higher rates of tuberculosis-related morbidity and mortality within 12 months after discharge in a referral hospital in Sub-Saharan Africa. BMC Infect Dis 2014;14:409. [PMID: 25047744 DOI: 10.1186/1471-2334-14-409] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
35 Mbeye NM, ter Kuile FO, Davies MA, Phiri KS, Egger M, Wandeler G; IeDEA-Southern Africa. Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health 2014;19:1057-67. [PMID: 25039469 DOI: 10.1111/tmi.12352] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
36 Geresu B, Misganaw D, Beyene Y. Retrospective evaluation of cotrimoxazole use as preventive therapy in people living with HIV/AIDS in Boru Meda Hospital. BMC Pharmacol Toxicol 2014;15:4. [PMID: 24507658 DOI: 10.1186/2050-6511-15-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
37 Mindachew M, Deribew A, Memiah P, Biadgilign S. Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J 2014;17:26. [PMID: 24932337 DOI: 10.11604/pamj.2014.17.26.2641] [Cited by in Crossref: 19] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
38 Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med 2014;370:41-53. [PMID: 24382064 DOI: 10.1056/NEJMoa1214901] [Cited by in Crossref: 88] [Cited by in F6Publishing: 91] [Article Influence: 11.0] [Reference Citation Analysis]
39 Ukwaja KN. Comment on “Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis”. Sci Transl Med 2013;5. [DOI: 10.1126/scitranslmed.3006386] [Reference Citation Analysis]
40 Wolff KA, Nguyen L. Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis. Expert Rev Anti Infect Ther 2012;10:971-81. [PMID: 23106273 DOI: 10.1586/eri.12.87] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
41 Moolphate S, Lawpoolsri S, Pungrassami P, Sanguanwongse N, Yamada N, Kaewkungwal J. Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. Glob J Health Sci 2013;5:60-70. [PMID: 23777722 DOI: 10.5539/gjhs.v5n4p60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
42 Chehab JC, Vilakazi-Nhlapo AK, Vranken P, Peters A, Klausner JD. Current integration of tuberculosis (TB) and HIV services in South Africa, 2011. PLoS One 2013;8:e57791. [PMID: 23469242 DOI: 10.1371/journal.pone.0057791] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
43 Howard AA, Gasana M, Getahun H, Harries A, Lawn SD, Miller B, Nelson L, Sitienei J, Coggin WL. PEPFAR support for the scaling up of collaborative TB/HIV activities. J Acquir Immune Defic Syndr 2012;60 Suppl 3:S136-44. [PMID: 22797735 DOI: 10.1097/QAI.0b013e31825cfe8e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
44 Burtle D, Welfare W, Elden S, Mamvura C, Vandelanotte J, Petherick E, Walley J, Wright J. Introduction and evaluation of a 'pre-ART care' service in Swaziland: an operational research study. BMJ Open 2012;2:e000195. [PMID: 22422913 DOI: 10.1136/bmjopen-2011-000195] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
45 Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis 2011;204 Suppl 4:S1168-78. [PMID: 21996699 DOI: 10.1093/infdis/jir449] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
46 Suthar AB, Granich R, Mermin J, Van Rie A. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ 2012;90:128C-38C. [PMID: 22423164 DOI: 10.2471/BLT.11.093260] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
47 Hutchinson E, Parkhurst J, Phiri S, Gibb DM, Chishinga N, Droti B, Hoskins S. National policy development for cotrimoxazole prophylaxis in Malawi, Uganda and Zambia: the relationship between Context, Evidence and Links. Health Res Policy Syst 2011;9 Suppl 1:S6. [PMID: 21679387 DOI: 10.1186/1478-4505-9-S1-S6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
48 Mills HL, Cohen T, Colijn C. Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure. J R Soc Interface 2011;8:1510-20. [PMID: 21508012 DOI: 10.1098/rsif.2011.0160] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
49 Ogwang S, Nguyen HT, Sherman M, Bajaksouzian S, Jacobs MR, Boom WH, Zhang GF, Nguyen L. Bacterial conversion of folinic acid is required for antifolate resistance. J Biol Chem 2011;286:15377-90. [PMID: 21372133 DOI: 10.1074/jbc.M111.231076] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
50 Hutchinson E, Droti B, Gibb D, Chishinga N, Hoskins S, Phiri S, Parkhurst J. Translating evidence into policy in low-income countries: lessons from co-trimoxazole preventive therapy. Bull World Health Organ 2011;89:312-6. [PMID: 21479096 DOI: 10.2471/BLT.10.077743] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
51 Köser CU, Summers DK, Archer JA. Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010;54:4951-2; author reply 4952. [PMID: 20947864 DOI: 10.1128/AAC.00876-10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
52 Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 2010;24 Suppl 5:S57-65. [PMID: 21079430 DOI: 10.1097/01.aids.0000391023.03037.1f] [Cited by in Crossref: 62] [Cited by in F6Publishing: 81] [Article Influence: 5.2] [Reference Citation Analysis]